Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

N/AEnrolling By InvitationNCT06730477

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology500 enrolled

Overview

The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations. The main objective is to identify potential biomarkers that can predict the efficacy of targeted therapy through plasma exosomes and to explore strategies to reverse drug resistance to targeted therapy. Biological specimens and medical imaging data will be collected from patients already receiving targeted therapy as a first-line treatment, and followed-up will be conducted to analyze prognosis based on different patterns.

The medical imaging data will be collected retrospectively and prospectively, and the blood samples and tumor tissues will be collected prospectively.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Lung Adenocarcinoma EGFR Activating Mutation

Interventions

observational studyOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathological examination confirmed lung adenocarcinoma * No other type of tumor was present * Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified * Receive targeted therapy with or without chemotherapy as first-line treatment * ≥ 18 years and ≤80 years old Exclusion Criteria: * History of other malignant tumors * Irregular treatment or poor compliance * Incomplete clinical information or lost to follow-up

Outcomes

Primary Outcomes

progression-free survival

The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.

Time frame: A two-year period after starting treatment (Regular follow-up every three months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)

Secondary Outcomes

Overall survival

The survival time after receiving targeted therapy combined with or without chemotherapy as first-line treatment

Time frame: A three-year period after starting treatment (Regular follow-up every six months after receiving targeted therapy combined with or without chemotherapy as first-line treatment)